2016. Preclinical formulation for the pharmacokinetics and efficacy of GBO-006, a selective polo like kinase 2 (PLK2) inhibitor for the treatment of triple negative breast cancer. ADMET and DMPK. 4, 4 (Dec. 2016), 314–326. DOI:https://doi.org/10.5599/admet.4.4.341.